A detailed history of State Street Corp transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, State Street Corp holds 5,143,534 shares of NTLA stock, worth $73.6 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
5,143,534
Previous 4,362,780 17.9%
Holding current value
$73.6 Million
Previous $97.6 Million 8.25%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$19.72 - $27.36 $15.4 Million - $21.4 Million
780,754 Added 17.9%
5,143,534 $106 Million
Q2 2024

Aug 14, 2024

SELL
$20.02 - $27.22 $4.71 Million - $6.4 Million
-235,042 Reduced 5.11%
4,362,780 $97.6 Million
Q1 2024

May 15, 2024

SELL
$23.82 - $32.8 $3.29 Million - $4.53 Million
-138,039 Reduced 2.91%
4,597,822 $126 Million
Q4 2023

Feb 14, 2024

BUY
$23.16 - $32.34 $23.2 Million - $32.4 Million
1,002,936 Added 26.87%
4,735,861 $144 Million
Q3 2023

Nov 14, 2023

BUY
$31.62 - $45.78 $7.59 Million - $11 Million
240,134 Added 6.88%
3,732,925 $118 Million
Q2 2023

Aug 14, 2023

SELL
$34.58 - $46.03 $1.62 Million - $2.16 Million
-46,847 Reduced 1.32%
3,492,791 $142 Million
Q1 2023

May 15, 2023

SELL
$33.3 - $44.82 $7.16 Million - $9.64 Million
-215,106 Reduced 5.73%
3,539,638 $132 Million
Q4 2022

Feb 14, 2023

BUY
$33.21 - $62.69 $35.4 Million - $66.9 Million
1,067,025 Added 39.7%
3,754,744 $131 Million
Q3 2022

Nov 15, 2022

SELL
$53.92 - $71.7 $24.6 Million - $32.7 Million
-456,092 Reduced 14.51%
2,687,719 $150 Million
Q2 2022

Aug 15, 2022

BUY
$38.49 - $76.21 $28.7 Million - $56.9 Million
746,284 Added 31.13%
3,143,811 $163 Million
Q1 2022

May 16, 2022

BUY
$58.27 - $118.99 $32.4 Million - $66.2 Million
556,076 Added 30.2%
2,397,527 $174 Million
Q4 2021

Feb 14, 2022

BUY
$100.76 - $138.36 $18.1 Million - $24.9 Million
179,721 Added 10.82%
1,841,451 $218 Million
Q3 2021

Nov 15, 2021

SELL
$132.37 - $176.78 $15.4 Million - $20.6 Million
-116,612 Reduced 6.56%
1,661,730 $223 Million
Q2 2021

Aug 16, 2021

SELL
$60.88 - $161.91 $3.06 Million - $8.14 Million
-50,297 Reduced 2.75%
1,778,342 $288 Million
Q1 2021

May 17, 2021

SELL
$46.59 - $83.68 $19.3 Million - $34.7 Million
-414,101 Reduced 18.46%
1,828,639 $147 Million
Q4 2020

Feb 16, 2021

SELL
$18.83 - $63.53 $15.4 Million - $51.8 Million
-815,858 Reduced 26.67%
2,242,740 $122 Million
Q3 2020

Nov 10, 2020

BUY
$17.47 - $24.93 $12.9 Million - $18.4 Million
739,310 Added 31.88%
3,058,598 $60.8 Million
Q2 2020

Aug 14, 2020

BUY
$11.14 - $22.87 $6.62 Million - $13.6 Million
594,605 Added 34.48%
2,319,288 $48.8 Million
Q1 2020

May 11, 2020

BUY
$9.44 - $15.58 $16.3 Million - $26.9 Million
1,724,683 New
1,724,683 $21.1 Million

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $1.09B
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track State Street Corp Portfolio

Follow State Street Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.